Please login to order a test.
Cancer antigen 125-II (CA 125), serial monitor report; lipid-associated sialic acid (LASA), serial monitor report
Monitor the course of uterine cancer, patient response to treatment, and disease recurrence
This profile should not be used as a diagnostic or screening test for cancer. The LASA procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.
See individual tests.
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Causes for Rejection
Hemolysis; whole blood specimen
The account must submit the patient's Social Security number to monitor. Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy.
This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|485136||Uterine Cancer Monitor Prof||002321||Cancer Antigen (CA) 125||U/mL||10334-1|
|485136||Uterine Cancer Monitor Prof||480001||Serial Monitoring||N/A|
|485136||Uterine Cancer Monitor Prof||480002||Serial Monitoring||N/A|
|485136||Uterine Cancer Monitor Prof||480133||Lipid-Associated Sialic Acid||mg/dL||2943-9|